Jump to content

Pfizer, BioNTech say their COVID-19 vaccine is more than 90% effective


snoop1130

Recommended Posts

Pfizer, BioNTech say their COVID-19 vaccine is more than 90% effective

By Michael Erman and Julie Steenhuysen

 

2020-11-09T115039Z_1_LYNXMPEGA80QX_RTROPTP_4_HEALTH-CORONAVIRUS-VACCINES-PFIZER.JPG

FILE PHOTO: A sign is pictured outside Pfizer Headquarters in the Manhattan borough of New York City, New York, U.S., July 22, 2020. REUTERS/Carlo Allegri

 

(Reuters) - Pfizer Inc on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against a pandemic that has killed over 1 million people, roiled the world's economy and upended daily life.

 

Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek U.S. emergency use authorization later this month.

 

If authorized, the number of vaccine doses will initially be limited. Many questions also remain including how long the vaccine will provide protection. However the news provides hope that other vaccines in development against the novel coronavirus may also prove effective.

 

"Today is a great day for science and humanity," Albert Bourla, Pfizer's chairman and chief executive, said in a statement. "We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen."

 

Pfizer expects to seek broad U.S. emergency use authorization of the vaccine for people aged 16 to 85. To do so, it will need to have collected two months of safety data on around half of the study's roughly 44,000 participants, expected in late November.

 

"I'm near ecstatic," Bill Gruber, one of Pfizer's top vaccine scientists, said in an interview. "This is a great day for public health and for the potential to get us all out of the circumstances we're now in."

 

Pfizer said the interim analysis was conducted after 94 participants in the trial developed COVID-19, examining how many of them received the vaccine versus a placebo.

 

The company did not break down exactly how many of those who fell ill received the vaccine. Still, over 90% effectiveness implies that no more than 8 of the 94 people who caught COVID-19 had been given the vaccine, which was administered in two shots about three weeks apart.

 

The efficacy rate is well above the 50% effectiveness required by the U.S. Food and Drug Administration for a coronavirus vaccine.

To confirm its efficacy rate, Pfizer said it will continue the trial until there are 164 COVID-19 cases among participants. Given the recent spike in U.S. infection rates, that number could be reached by early December, Gruber said.

 

The data have yet to be peer-reviewed or published in a medical journal. Pfizer said it would do so once it has results from the entire trial.

 

Pfizer and BioNTech have a $1.95 billion contract with the U.S. government to deliver 100 million vaccine doses beginning this year. They have also reached supply agreements with the European Union, the UK, Canada and Japan.

 

To save time, the companies began manufacturing the vaccine before they knew whether it would be effective. They now expect to produce up to 50 million doses or enough vaccine to protect 25 million people this year.

 

Pfizer said it expects to produce up to 1.3 billion doses of the vaccine in 2021.

 

GLOBAL RACE

 

The global race for a vaccine has seen wealthier countries forge multibillion-dollar supply deals with drugmakers like Pfizer, AstraZeneca Plc and Johnson & Johnson Inc, raising questions over when middle income and poorer nations will get access to inoculations.

 

The U.S. quest for a vaccine has been the Trump administration's central response to the pandemic. The United States has the world's highest known number of COVID-19 cases and deaths with more than 10 million infections and more than 237,000 fatalities.

 

President Donald Trump repeatedly assured the public that his administration would likely identify a successful vaccine in time for the presidential election, held last Tuesday. On Saturday, Democratic rival Joe Biden was declared the winner.

 

Vaccines are seen as essential tools to help end the health crisis that has shuttered businesses and left millions out of work. Millions of children whose schools were closed in March remain in remote learning programs.

 

Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against COVID-19, which on Sunday exceeded 50 million infections since the novel coronavirus first emerged late last year in China.

 

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines.

 

Moderna Inc, whose vaccine candidate employs similar technology, is expected to report results from its large-scale trial later this month. The mRNA technology is designed to trigger an immune response without using pathogens, such as actual virus particles.

 

Pfizer alone will not have the capacity to immediately provide enough vaccines for the entire United States. The Trump administration has said it will have enough supply for all of the 330 million U.S. residents who wish to be vaccinated by the middle of 2021.

 

The U.S. government has said the vaccines will be provided for free to Americans, including the insured, uninsured and those in government health programs such as Medicare.

 

reuters_logo.jpg

-- © Copyright Reuters 2020-11-09
 
  • Like 2
Link to comment
Share on other sites

1 hour ago, snoop1130 said:

Pfizer said the interim analysis was conducted after 94 participants in the trial developed COVID-19, examining how many of them received the vaccine versus a placebo.

 

The company did not break down exactly how many of those who fell ill received the vaccine. Still, over 90% effectiveness implies that no more than 8 of the 94 people who caught COVID-19 had been given the vaccine, which was administered in two shots about three weeks apart.

 

 

Maybe someone can explain, but I find the above a rather strange way to test effectiveness.

 

So if they didn't give anyone the vaccine, and they all caught COVID, that means 100% effectiveness?

  • Like 1
  • Confused 1
Link to comment
Share on other sites

'90% effective'

For exactly whom?

Apply to serverly, moderately, lightly infected; young vs old; male vs female; medically vulnerable due to known/7nknown pre-existing medical conditions, etc.?

90% effective with one, two, multiple injections?

More disclosure is needed.

  • Thanks 1
Link to comment
Share on other sites

1 hour ago, Srikcir said:

'90% effective'

For exactly whom?

Apply to serverly, moderately, lightly infected; young vs old; male vs female; medically vulnerable due to known/7nknown pre-existing medical conditions, etc.?

90% effective with one, two, multiple injections?

More disclosure is needed.

Applied to healthy people,  not to infected people. 

2 injections,  3 weeks apart. 

 

About the different groups (age, sex, vulnerable) they didn't say much afaik.

 

Why don't you just read the news yourself? 

Link to comment
Share on other sites

1 hour ago, Srikcir said:

'90% effective'

For exactly whom?

Apply to serverly, moderately, lightly infected; young vs old; male vs female; medically vulnerable due to known/7nknown pre-existing medical conditions, etc.?

90% effective with one, two, multiple injections?

More disclosure is needed.

90% effective in preventing any infection

 

the study participants included all ages and both sexes and people with some pre-existing conditions but with so very few infections at all in the vaccinated group one would nto be able to stratify it.

 

In any case pre-existing conditions etc are not thought to be risk factors for becoming infected, rather they are risk factors for severity of disease once infected.

  • Like 2
Link to comment
Share on other sites

15 hours ago, eisfeld said:

These tests always give a certain amount of people the real vaccine and the others placebos. Of course they don't hand out 100% placebos, that would be pointless. It's not like Pfizer is new to the game and doesn't know how to conduct a study.

It's not like they tell the truth either. https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history

 

Link to comment
Share on other sites

3 hours ago, Sheryl said:

90% effective in preventing any infection

 

the study participants included all ages and both sexes and people with some pre-existing conditions but with so very few infections at all in the vaccinated group one would nto be able to stratify it.

 

In any case pre-existing conditions etc are not thought to be risk factors for becoming infected, rather they are risk factors for severity of disease once infected.

I read an American article that claimed the 90% effectiveness but only for one month.

Great way to make money if you need the vaccine every month.

  • Confused 1
Link to comment
Share on other sites

As usual, the Pfizer announcement is very general without providing much useful data. We only know that, at the time of the interim report, 94 persons involved in the trial were infected with COVID-19 and that the claimed efficacy was 90% but apparently no specific data are provided for the vaccine- and placebo groups.  A further assessment will be  made when the number of infections reaches 164.

 

There is another major obstacle, that is the vaccine has to be transported and stored at -70oC. Even in many Western countries this is a problem and will mean that many GPs will not be able to administer the vaccine.

 

 

Link to comment
Share on other sites

1 hour ago, GreasyFingers said:

I read an American article that claimed the 90% effectiveness but only for one month.

Great way to make money if you need the vaccine every month.

Can you provide a source for that claim?

 

And even if it were true, it would be a fantastic step in the right direction as it reduces the problem from a huge "how can we protect us from getting infected" to "now that we know how to protect us, how do we prolong the effect?" which is a much, much easier problem to solve. Worst case you make it cost in the range of $5 with enough economy of scale.

  • Like 2
Link to comment
Share on other sites

36 minutes ago, Sheryl said:

 There is no printed article, anywhere, that discusses this yet as the results only just announced.

 

The duration of protection is still unknown but is certainly longer than 1 month; they followed people for about 6 months I think. . Only 2 doses are currently recommended.

 

 

 

Maybe he's referring to this article

 

https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/

In keeping with guidance from the Food and Drug Administration, the companies will not file for an emergency use authorization to distribute the vaccine until they reach another milestone: when half of the patients in their study have been observed for any safety issues for at least two months following their second dose.

 

Because the vaccine has been studied for only a matter of months, it is impossible to say how long it will protect against infection with the virus

  • Like 1
Link to comment
Share on other sites

40 minutes ago, Sheryl said:

 There is no printed article, anywhere, that discusses this yet as the results only just announced.

 

The duration of protection is still unknown but is certainly longer than 1 month; they followed people for about 6 months I think. . Only 2 doses are currently recommended.

You think wrong, the phase III trial only started at the end of July. Data for longer periods only apply to small scale phase I/II trials that furthermore involved low(er) risk groups (mostly white, age 18-55). 

Link to comment
Share on other sites

46 minutes ago, Susco said:

 

 

 

Maybe he's referring to this article

 

https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/

In keeping with guidance from the Food and Drug Administration, the companies will not file for an emergency use authorization to distribute the vaccine until they reach another milestone: when half of the patients in their study have been observed for any safety issues for at least two months following their second dose.

 

Because the vaccine has been studied for only a matter of months, it is impossible to say how long it will protect against infection with the virus

Nowhere in that article (or any other) does it state that the effectiveness is for only 1 month.

 

indeed the 90% effectiveness is based on numbers who developed COVID over a period of time, not just 30 days.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.







×
×
  • Create New...